Cullinan Associates’s Danaher DHR Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $229K | Hold |
1,200
| – | – | 0.02% | 199 |
|
|
2026
Q1 | $228K | Hold |
1,200
| – | – | 0.02% | 199 |
|
|
2025
Q4 | $275K | Hold |
1,200
| – | – | 0.02% | 195 |
|
|
2025
Q3 | $238K | Hold |
1,200
| – | – | 0.02% | 202 |
|
|
2025
Q2 | $237K | Sell |
1,200
-100
| -8% | -$19.4K | 0.02% | 205 |
|
|
2025
Q1 | $267K | Hold |
1,300
| – | – | 0.02% | 196 |
|
|
2024
Q4 | $298K | Hold |
1,300
| – | – | 0.02% | 195 |
|
|
2024
Q3 | $353K | Sell |
1,300
-500
| -28% | -$132K | 0.02% | 203 |
|
|
2024
Q2 | $450K | Hold |
1,800
| – | – | 0.03% | 192 |
|
|
2024
Q1 | $449K | Sell |
1,800
-600
| -25% | -$146K | 0.03% | 196 |
|
|
2023
Q4 | $555K | Sell |
2,400
-307
| -11% | -$65.3K | 0.03% | 178 |
|
|
2023
Q3 | $595K | Hold |
2,707
| – | – | 0.03% | 179 |
|
|
2023
Q2 | $576K | Buy |
2,707
+677
| +33% | +$143K | 0.03% | 185 |
|
|
2023
Q1 | $454K | Sell |
2,030
-1,128
| -36% | -$257K | 0.03% | 196 |
|
|
2022
Q4 | $743K | Buy |
3,158
+225
| +8% | +$52.2K | 0.04% | 180 |
|
|
2022
Q3 | $672K | Buy |
2,933
+79
| +3% | +$19.3K | 0.04% | 161 |
|
|
2022
Q2 | $641K | Buy |
+2,854
| New | +$657K | 0.04% | 162 |
|
|
2022
Q1 | – | Sell |
-711
| Closed | -$207K | – | 238 |
|
|
2021
Q4 | $207K | Sell |
711
-1,756
| -71% | -$484K | 0.01% | 228 |
|
|
2021
Q3 | $666K | Sell |
2,467
-321
| -12% | -$87.4K | 0.04% | 163 |
|
|
2021
Q2 | $663K | Hold |
2,788
| – | – | 0.04% | 155 |
|
|
2021
Q1 | $556K | Buy |
2,788
+451
| +19% | +$91.6K | 0.03% | 152 |
|
|
2020
Q4 | $460K | Buy |
+2,337
| New | +$469K | 0.03% | 153 |
|
|
2019
Q3 | – | Sell |
-47,946
| Closed | -$6.08M | – | 184 |
|
|
2019
Q2 | $6.08M | Sell |
47,946
-8,572
| -15% | -$1.01M | 0.44% | 63 |
|
|
2019
Q1 | $6.62M | Buy |
56,518
+6,029
| +12% | +$618K | 0.5% | 55 |
|
|
2018
Q4 | $4.62M | Buy |
50,489
+4,534
| +10% | +$412K | 0.38% | 65 |
|
|
2018
Q3 | $4.43M | Sell |
45,955
-3,609
| -7% | -$329K | 0.32% | 85 |
|
|
2018
Q2 | $4.34M | Buy |
49,564
+1,957
| +4% | +$174K | 0.33% | 84 |
|
|
2018
Q1 | $4.13M | Buy |
47,607
+3,440
| +8% | +$301K | 0.31% | 88 |
|
|
2017
Q4 | $3.63M | Sell |
44,167
-2,256
| -5% | -$183K | 0.27% | 95 |
|
|
2017
Q3 | $3.53M | Buy |
46,423
+8,235
| +22% | +$609K | 0.27% | 96 |
|
|
2017
Q2 | $2.86M | Buy |
38,188
+5,504
| +17% | +$412K | 0.22% | 102 |
|
|
2017
Q1 | $2.48M | Sell |
32,684
-1,861
| -5% | -$139K | 0.2% | 110 |
|
|
2016
Q4 | $2.38M | Sell |
34,545
-1,015
| -3% | -$70.5K | 0.2% | 111 |
|
|
2016
Q3 | $2.47M | Sell |
35,560
-40,803
| -53% | -$2.89M | 0.21% | 107 |
|
|
2016
Q2 | $5.18M | Sell |
76,363
-149
| -0.2% | -$9.75K | 0.42% | 65 |
|
|
2016
Q1 | $4.88M | Buy |
76,512
+1,786
| +2% | +$106K | 0.42% | 70 |
|
|
2015
Q4 | $4.67M | Buy |
74,726
+15,771
| +27% | +$987K | 0.41% | 66 |
|
|
2015
Q3 | $3.38M | Sell |
58,955
-149
| -0.3% | -$8.8K | 0.31% | 76 |
|
|
2015
Q2 | $3.4M | Buy |
59,104
+3,943
| +7% | +$226K | 0.28% | 83 |
|
|
2015
Q1 | $3.15M | Buy |
+55,161
| New | +$3.16M | 0.24% | 87 |
|
Other funds holding DHR
Cullinan Associates's DHR Position: Q2 2026 in Review
Cullinan Associates held its Danaher (DHR) position steady in Q2 2026 at 1,200 shares worth $229K. The position accounts for 0.02% of the portfolio, ranked #199.
Cullinan Associates first reported a position in DHR in Q1 2015 and has held it in 40 quarters since. The position peaked at $6.62M in Q1 2019. 2,094 funds tracked by Wall St. Rank hold DHR as of Q2 2026.
- Cullinan Associates held 1,200 shares of Danaher worth $229K as of Q2 2026.
- Cullinan Associates left its Danaher share count unchanged in Q2 2026.
- Danaher made up 0.02% of Cullinan Associates's portfolio in Q2 2026, its #199 holding.
- Cullinan Associates first reported a position in Danaher in Q1 2015 and has held it in 40 quarters since.
- Cullinan Associates's Danaher position peaked at $6.62M in Q1 2019.
- 2,094 funds tracked by Wall St. Rank held Danaher as of Q2 2026.
Based on Cullinan Associates's 13F filing for Q2 2026, filed 29 Jul 2026.